TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Manipulation, Exercise, and Self-Care for Low Back Pain
Brief Summary: The broad, long term objective of this interdisciplinary research is to identify effective therapies for low back pain sufferers and to increase our understanding of this important condition. The primary aim is to examine the relative efficacy of chiropractic spinal manipulation, rehabilitative exercise, and self-care education in terms of patient-rated outcomes in the short and long term for non-acute low back pain.


Options:
A: Intervention Type: PROCEDURE; Name: Chiropractic Spinal Manipulation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Self-care; Assigned to Arm(s): N/A
B: Arm Label: Graded Activity; Type: ACTIVE_COMPARATOR; Interventions: Other: Graded Activity, Other: Supervised Exercises | Arm Label: Supervised exercises; Type: ACTIVE_COMPARATOR; Interventions: Other: Graded Activity, Other: Supervised Exercises | Intervention Type: OTHER; Name: Graded Activity; Assigned to Arm(s): Graded Activity, Supervised exercises | Intervention Type: OTHER; Name: Supervised Exercises; Assigned to Arm(s): Graded Activity, Supervised exercises
C: Arm Label: TrA exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Isolated Transversus abdominis (TrA) exercise | Arm Label: sling exercise; Type: EXPERIMENTAL; Interventions: Behavioral: sling exercise | Arm Label: group exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: group exercise | Intervention Type: BEHAVIORAL; Name: Isolated Transversus abdominis (TrA) exercise; Assigned to Arm(s): TrA exercise | Intervention Type: BEHAVIORAL; Name: sling exercise; Assigned to Arm(s): sling exercise | Intervention Type: BEHAVIORAL; Name: group exercise; Assigned to Arm(s): group exercise
D: Arm Label: Core stabilization and psychosocial education; Type: EXPERIMENTAL; Interventions: Behavioral: Core stabilization and psychosocial education | Arm Label: Core stabilization exercise only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Core stabilization exercise only | Arm Label: Psychosocial education class only.; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychosocial education class only | Arm Label: Traditional Army training; Type: OTHER; Interventions: Behavioral: Traditional Army training | Intervention Type: BEHAVIORAL; Name: Traditional Army training; Assigned to Arm(s): Traditional Army training | Intervention Type: BEHAVIORAL; Name: Core stabilization exercise only; Assigned to Arm(s): Core stabilization exercise only | Intervention Type: BEHAVIORAL; Name: Psychosocial education class only; Assigned to Arm(s): Psychosocial education class only. | Intervention Type: BEHAVIORAL; Name: Core stabilization and psychosocial education; Assigned to Arm(s): Core stabilization and psychosocial education

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Manipulation, Exercise, and Self-Care for Neck Pain
Brief Summary: The purpose of this study is to compare three treatments for neck pain: 1) rehabilitative exercise, 2) chiropractic spinal manipulation combined with rehabilitative exercise, and 3) self-care education.


Options:
A: Arm Label: 1 Manual Therapy Utrecht; Type: EXPERIMENTAL; Interventions: Other: Manual Therapy Utrecht | Arm Label: 2 Physical Therapy - Exercise Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical Therapy | Intervention Type: OTHER; Name: Manual Therapy Utrecht; Assigned to Arm(s): 1 Manual Therapy Utrecht | Intervention Type: OTHER; Name: Physical Therapy; Assigned to Arm(s): 2 Physical Therapy - Exercise Therapy
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: spinal manipulation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: Spinal manipulation + exercises | Intervention Type: OTHER; Name: spinal manipulation; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Spinal manipulation + exercises; Assigned to Arm(s): 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Chiropractic + Supervised Rehabilitative Exercise | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Supervised Rehabilitative Exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care education | Intervention Type: PROCEDURE; Name: Chiropractic + Supervised Rehabilitative Exercise; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Supervised Rehabilitative Exercise; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Self-care education; Assigned to Arm(s): 3
D: Intervention Type: PROCEDURE; Name: Chiropractic spinal manipulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Self-care; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Non-Steroidal anti-inflammatory drugs (NSAIDS); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tylenol with codeine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease
Brief Summary: This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.


Options:
A: Arm Label: 1mg rasagiline; Type: EXPERIMENTAL; Interventions: Drug: Rasagiline Mesylate | Arm Label: 2mg rasagiline; Type: EXPERIMENTAL; Interventions: Drug: Rasagiline Mesylate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Rasagiline Mesylate; Assigned to Arm(s): 1mg rasagiline | Intervention Type: DRUG; Name: Rasagiline Mesylate; Assigned to Arm(s): 2mg rasagiline | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: pramipexole; Type: EXPERIMENTAL; Interventions: Drug: Pramipexole | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Pramipexole; Assigned to Arm(s): pramipexole | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: occupational therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Occupational Therapy | Arm Label: No occupational therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Occupational Therapy; Assigned to Arm(s): occupational therapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pardoprunox | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Pardoprunox | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Pardoprunox | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pardoprunox; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pardoprunox; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Pardoprunox; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease
Brief Summary: This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: health education | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: hand hygiene | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: hand hygiene, Device: face masks | Intervention Type: BEHAVIORAL; Name: hand hygiene; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: health education; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: face masks; Assigned to Arm(s): 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pardaprunox | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: pramipexole | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Pardaprunox; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pramipexole; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): 3
C: Intervention Type: DRUG; Name: amantadine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oseltamivir phosphate; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pardoprunox | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Pardoprunox | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Pardoprunox | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pardoprunox; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pardoprunox; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Pardoprunox; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized Comparison of Mifepristone and Misoprostol Administered Simultaneously Versus 24 Hours Apart for Abortion Through 63 Days
Brief Summary: This is a multicenter, randomized study. 564 healthy women, age 18 years or older, with an intrauterine pregnancy, and requesting a medical abortion, will be recruited to participate in this prospective clinical trial. This study will provide an evaluation of oral mifepristone 200 mg and vaginal misoprostol 800 mcg administered simultaneously in women up to 63 days gestation. The aims of the study are to compare the complete abortion rates, at 7 and 14 days after misoprostol administration, when using mifepristone 200 mg orally and misoprostol 800 mcg vaginally are administered simultaneously and 24 hours apart in women up to 63 days gestation. Assessment of side effects (nausea, vomiting, pain) as well as acceptability will be done using pre and post-study questionnaires, and visual analogue scales. Complete abortion rate within 24 hours is expected to be 90%


Options:
A: Arm Label: Women seeking medical abortion; Type: N/A; Interventions: Drug: Mifepristone, misoprostol | Intervention Type: DRUG; Name: Mifepristone, misoprostol; Assigned to Arm(s): Women seeking medical abortion
B: Arm Label: Mifepristone-misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone and misoprostol | Intervention Type: DRUG; Name: Mifepristone and misoprostol; Assigned to Arm(s): Mifepristone-misoprostol
C: Arm Label: clinic administration of mifepristone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: home administration of mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): home administration of mifepristone
D: Intervention Type: DRUG; Name: mifepristone and misoprostol; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized Comparison of Mifepristone and Misoprostol Administered Simultaneously Versus 24 Hours Apart for Abortion Through 63 Days
Brief Summary: This is a multicenter, randomized study. 564 healthy women, age 18 years or older, with an intrauterine pregnancy, and requesting a medical abortion, will be recruited to participate in this prospective clinical trial. This study will provide an evaluation of oral mifepristone 200 mg and vaginal misoprostol 800 mcg administered simultaneously in women up to 63 days gestation. The aims of the study are to compare the complete abortion rates, at 7 and 14 days after misoprostol administration, when using mifepristone 200 mg orally and misoprostol 800 mcg vaginally are administered simultaneously and 24 hours apart in women up to 63 days gestation. Assessment of side effects (nausea, vomiting, pain) as well as acceptability will be done using pre and post-study questionnaires, and visual analogue scales. Complete abortion rate within 24 hours is expected to be 90%


Options:
A: Intervention Type: DRUG; Name: mifepristone and misoprostol; Assigned to Arm(s): N/A
B: Arm Label: misoprostol by midwife; Type: OTHER; Interventions: Other: misoprostol by midwife | Arm Label: Misoprostol by physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: misoprostol by midwife; Assigned to Arm(s): misoprostol by midwife
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1
D: Arm Label: midwife; Type: EXPERIMENTAL; Interventions: Other: Midwife | Arm Label: Physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Midwife; Assigned to Arm(s): midwife

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized, Multicenter Trial to Evaluate Continuation Rates, Side Effects and Acceptability of NuvaRing Versus OrthoEvra
Brief Summary: This is an open-label prospective, multicenter, randomized trial to compare continuation rates into the fourth cycle of women using either the NuvaRing or OrthoEvra. Five hundred women will be recruited at 9 centers nationwide to be randomly assigned to use either the NuvaRing or OrthoEvra for four months. Women must either be on the pill or have recently stopped the pill and be relatively satisfied with oral contraceptive use to qualify for enrollment. Two visits and two phone calls will be required.


Options:
A: Arm Label: 1 Standard Care (SC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Standard Care + Educational (SCE); Type: OTHER; Interventions: Behavioral: educational instruction in clinic | Arm Label: 3 Standard Care + Educational + Phone Calls (SCEP); Type: OTHER; Interventions: Behavioral: educational instruction and phone follow-up | Intervention Type: BEHAVIORAL; Name: educational instruction and phone follow-up; Assigned to Arm(s): 3 Standard Care + Educational + Phone Calls (SCEP) | Intervention Type: BEHAVIORAL; Name: educational instruction in clinic; Assigned to Arm(s): 2 Standard Care + Educational (SCE)
B: Arm Label: Contraceptive vaginal ring; Type: ACTIVE_COMPARATOR; Interventions: Device: NuvaRing | Arm Label: Oral contraceptive pill; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ortho Tri-cyclen Lo | Intervention Type: DRUG; Name: Ortho Tri-cyclen Lo; Assigned to Arm(s): Oral contraceptive pill | Intervention Type: DEVICE; Name: NuvaRing; Assigned to Arm(s): Contraceptive vaginal ring
C: Intervention Type: BEHAVIORAL; Name: Quick start oral contraceptive initiation; Assigned to Arm(s): N/A
D: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: ethinyl estradiol/norelgestromin transdermal contraceptive | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ethinyl estradiol/etonogestrel vaginal ring | Intervention Type: DRUG; Name: ethinyl estradiol/etonogestrel vaginal ring; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ethinyl estradiol/norelgestromin transdermal contraceptive; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-term Safety and Effectiveness of OROS (Methylphenidate HCl) in Children With ADHD
Brief Summary: The purpose of this study is to evaluate the long-term safety and effectiveness of OROSÂ® Methylphenidate HCl (a central nervous system stimulant) in children with attention deficit hyperactivity disorder (ADHD).


Options:
A: Arm Label: Aripirazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Quetiapine prolong; Type: EXPERIMENTAL; Interventions: Drug: Quetiapine | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripirazole | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Quetiapine prolong
B: Arm Label: OROS MPH; Type: EXPERIMENTAL; Interventions: Drug: OROS MPH | Arm Label: atomoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atomoxetine | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: OROS MPH; Assigned to Arm(s): OROS MPH | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): atomoxetine
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: methylphenidate HCl | Intervention Type: DRUG; Name: methylphenidate HCl; Assigned to Arm(s): 001
D: Arm Label: OROS MPH; Type: EXPERIMENTAL; Interventions: Drug: methylphenidate HCl (Concerta) | Intervention Type: DRUG; Name: methylphenidate HCl (Concerta); Assigned to Arm(s): OROS MPH

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana
Brief Summary: Anti-HIV drug regimens have dramatically improved the rates of prevention of mother-to-child transmission (MTCT) of HIV in developed countries. However, little is known of the effectiveness of such regimens in developing countries, such as Botswana. This study will determine whether Trizivir (TZV), a single pill containing abacavir sulfate, lamivudine, and zidovudine (ABC/3TC/ZDV), or lopinavir/ritonavir (LPV/r) and lamivudine/zidovudine (3TC/ZDV) is more effective in reducing HIV-1 viral load and preventing MTCT among HIV infected pregnant women in Botswana.


Options:
A: Intervention Type: DRUG; Name: Trizivir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atazanavir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combivir; Assigned to Arm(s): N/A
B: Arm Label: maternal nevirapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: maternal placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: No intervention | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): maternal nevirapine | Intervention Type: DRUG; Name: No intervention; Assigned to Arm(s): maternal placebo
C: Intervention Type: DRUG; Name: Abacavir; Assigned to Arm(s): N/A
D: Arm Label: Trizivir (TZV) Arm; Type: EXPERIMENTAL; Interventions: Drug: Trizivir | Arm Label: Kaletra Arm; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine/Zidovudine, Drug: Lopinavir/Ritonavir | Arm Label: Nevirapine (NVP) Arm; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Intervention Type: DRUG; Name: Trizivir; Assigned to Arm(s): Trizivir (TZV) Arm | Intervention Type: DRUG; Name: Lamivudine/Zidovudine; Assigned to Arm(s): Kaletra Arm | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): Kaletra Arm | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Nevirapine (NVP) Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana
Brief Summary: Anti-HIV drug regimens have dramatically improved the rates of prevention of mother-to-child transmission (MTCT) of HIV in developed countries. However, little is known of the effectiveness of such regimens in developing countries, such as Botswana. This study will determine whether Trizivir (TZV), a single pill containing abacavir sulfate, lamivudine, and zidovudine (ABC/3TC/ZDV), or lopinavir/ritonavir (LPV/r) and lamivudine/zidovudine (3TC/ZDV) is more effective in reducing HIV-1 viral load and preventing MTCT among HIV infected pregnant women in Botswana.


Options:
A: Intervention Type: DRUG; Name: Zidovudine/Lamivudine and either Nevirapine or Nelfinavir; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding for 6 months postpartum; Assigned to Arm(s): N/A
B: Arm Label: Abrupt Weaning; Type: EXPERIMENTAL; Interventions: Other: abrupt weaning at 4 months | Arm Label: Exclusive breastfeeding per WHO guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: Continued exclusive breastfeeding | Intervention Type: OTHER; Name: abrupt weaning at 4 months; Assigned to Arm(s): Abrupt Weaning | Intervention Type: OTHER; Name: Continued exclusive breastfeeding; Assigned to Arm(s): Exclusive breastfeeding per WHO guidelines
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: HIV immune globulin solution | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: HIV immune globulin solution; Assigned to Arm(s): 3
D: Arm Label: Trizivir (TZV) Arm; Type: EXPERIMENTAL; Interventions: Drug: Trizivir | Arm Label: Kaletra Arm; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine/Zidovudine, Drug: Lopinavir/Ritonavir | Arm Label: Nevirapine (NVP) Arm; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Intervention Type: DRUG; Name: Trizivir; Assigned to Arm(s): Trizivir (TZV) Arm | Intervention Type: DRUG; Name: Lamivudine/Zidovudine; Assigned to Arm(s): Kaletra Arm | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): Kaletra Arm | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Nevirapine (NVP) Arm

Answer: D